Full video transcriptClick to expand
Auto-generated transcript of @medspaslo's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Nurse Kristi, what's your favorite peptide for good skin?
- 0:05GHKCO. Your favorite peptide for weight loss? That would be red-a-trutide triple agonist.
- 0:11Best peptide for recovery. That would be the Wolverine Stack. It includes BPC-157,
- 0:19the body protective compound, and TB-500. Best peptide for immunity.
- 0:25That would be thymosin alpha 1. Best peptide for longevity.
- 0:30Top 2, NAD, and thymosin alpha 1. What is your favorite peptide for mood boost?
- 0:37Definitely C-max. For a sex drive? PT-141. What's your favorite peptide for nerve pain?
- 0:45Neuropathy, nerve regeneration, that would be the PAP4. And your best peptide for deep sleep?
- 0:54Gamechanger D-SIP.
@medspaslo's peptide therapy claims need more evidence
Quick answer
This video features a nurse practitioner-style rapid-fire format recommending specific peptide compounds for distinct health outcomes including recovery, immunity, sleep, mood, neuropathy, and libido. Several compounds named, including BPC-157, TB-500, and DSIP, lack completed human randomized controlled trial data and are available primarily through compounding pharmacies operating in a regulatory gray zone. One compound named, PT-141 (bremelanotide), holds FDA approval for a specific indication, and retatrutide has phase 2 human trial data, which meaningfully separates those two from the rest of the list.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @medspaslo's peptide therapy claims need more evidence, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial
Primary human trial source for retatrutide obesity efficacy and safety discussions.
PubMed
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
Used when retatrutide pages touch liver-fat, MASLD, and metabolic outcomes.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
@medspaslo's peptide therapy claims need more evidence should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "@medspaslo's peptide therapy claims need more evidence" from MedSpa SLO. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: This video features a nurse practitioner-style rapid-fire format recommending specific peptide compounds for distinct health outcomes including recovery, immunity, sleep, mood, neuropathy, and libido.
The reason this review is not generic is the source wording and the canonical claim label "peptides everyone is talking about peptides right now but do you act." In this clip, the useful excerpt is: "Nurse Kristi, what's your favorite peptide for good skin?" That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
This video features a nurse practitioner-style rapid-fire format recommending specific peptide compounds for distinct health outcomes including recovery, immunity, sleep, mood, neuropathy, and libido.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This video features a nurse practitioner-style rapid-fire format recommending specific peptide compounds for distinct health outcomes including recovery, immunity, sleep, mood, neuropathy, and libido. Several compounds named, including BPC-157, TB-500, and DSIP, lack completed human randomized controlled trial data and are available primarily through compounding pharmacies operating in a regulatory gray zone. One compound named, PT-141 (bremelanotide), holds FDA approval for a specific indication, and retatrutide has phase 2 human trial data, which meaningfully separates those two from the rest of the list.
- PT-141 (bremelanotide) is the only compound on this list with full FDA approval, specifically for hypoactive sexual desire disorder in premenopausal women, per the 2019 Simon et al. phase 3 data.
- Retatrutide showed up to 17.5% weight reduction in a 2023 NEJM phase 2 trial, but it is not FDA-approved and should not be conflated with currently approved GLP-1 medications.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- PT-141 (bremelanotide) is the only compound on this list with full FDA approval, specifically for hypoactive sexual desire disorder in premenopausal women, per the 2019 Simon et al. phase 3 data.
- Retatrutide showed up to 17.5% weight reduction in a 2023 NEJM phase 2 trial, but it is not FDA-approved and should not be conflated with currently approved GLP-1 medications.
- BPC-157 has zero completed randomized controlled trials in humans as of 2024. All recovery claims for the 'Wolverine Stack' are based on animal model data only.
- NAD is a coenzyme, not a peptide. Grouping it with peptide therapy is a category error that matters when evaluating mechanism claims.
- Compounded peptides are not equivalent to FDA-approved drugs. Purity, sterility, and dosing consistency vary by pharmacy and are not subject to the same regulatory oversight.
- DSIP's supporting research is largely from Soviet-era studies with methodological limitations. No modern peer-reviewed human trial supports calling it a sleep gamechanger.
- GHK-Cu has the most skin-specific human data of any peptide on this list, though studies remain small. Pickart and Margolina (2018, Biomolecules) provide a reasonable review of the existing evidence.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @medspaslo actually say?
Nurse Kristie ran through a rapid-fire list of "best peptide" picks covering eight health goals: GHK-Cu for skin, retatrutide for weight loss, "the Wolverine Stack" (BPC-157 plus TB-500) for recovery, thymosin alpha-1 for immunity, NAD and thymosin alpha-1 for longevity, Semax for mood, PT-141 for sex drive, "PAP4" for nerve pain, and DSIP for deep sleep. The format was casual and confident, framed around a nurse's personal favorites rather than a clinical protocol. No dosing was mentioned, which is one thing they got right. But when a healthcare provider calls something a "gamechanger" on Instagram to 67,000 viewers, the bar for accuracy gets higher, not lower. Several of these compounds have legitimate research behind them. Several others are being sold on name recognition and bodybuilding forum lore more than on peer-reviewed evidence.
Does the science back this up?
It depends enormously on which peptide you pick. The evidence spectrum here is wide. GHK-Cu for skin has real, if modest, support. Retatrutide for weight loss is backed by phase 2 trial data. But "the Wolverine Stack" and DSIP are another story entirely.
Starting with the solid ground: GHK-Cu (copper peptide) has shown collagen-stimulating effects in cell studies and some small human trials (Pickart and Margolina, 2018, Biomolecules). Retatrutide is a legitimate triple agonist (GLP-1, GIP, glucagon) with a phase 2 trial published in the New England Journal of Medicine in 2023 showing meaningful weight reduction, though it is still in clinical development and not FDA-approved. Thymosin alpha-1 has immunomodulatory data, primarily from sepsis and hepatitis B contexts (Camerini et al., 2010, Thymus). PT-141 (bremelanotide) is actually FDA-approved for hypoactive sexual desire disorder in women, so that claim has the strongest regulatory footing of any on the list.
Then there is the softer end. BPC-157 and TB-500 recovery claims rest almost entirely on rodent studies. DSIP (delta sleep-inducing peptide) has decades-old Soviet-era research and almost no modern controlled human data. "PAP4" is not a standard clinical nomenclature, which makes independent verification close to impossible.
What did they get wrong (or right)?
They got PT-141 right. It has FDA approval. Give credit where it is due. Retatrutide is a real compound with real trial data, though calling it a "peptide for weight loss" without noting it is not approved and not the same as Ozempic or Mounjaro is a meaningful omission.
The "Wolverine Stack" framing is where this gets genuinely problematic. Branding an unapproved combination of two peptides with essentially no human clinical trials as a recovery protocol, and naming it after a comic book character with superhuman healing, is marketing dressed up as medicine. BPC-157 does not have a single completed, published randomized controlled trial in humans as of 2024. TB-500's human data is similarly absent outside of theoretical mechanisms. Presenting these as established clinical tools to a 67,000-person audience is an overreach.
Calling NAD a peptide is also technically wrong. NAD (nicotinamide adenine dinucleotide) is a coenzyme, not a peptide. It is sometimes administered via IV at med spas alongside peptide protocols, but grouping it under "favorite peptides" reflects either a loose use of terminology or a category error that should have been corrected before posting.
What should you actually know?
Most peptides discussed in this video are compounded, meaning they are mixed by compounding pharmacies and are not FDA-approved drugs. This does not make them automatically dangerous, but it does mean the purity, dosage consistency, and long-term safety data that come with approved drugs simply do not exist for most of these compounds. Compounded BPC-157 is not the same as a drug that has passed phase 3 trials. Full stop.
If you are considering any of these therapies, the questions worth asking your provider are: What human trial data supports this use? Is this compound legal to prescribe in my state? What are the known side effect profiles? And critically, is this being recommended because the evidence supports it, or because it is popular right now?
A nurse recommending peptides on Instagram is not the same as a peer-reviewed treatment guideline. That does not mean the recommendations are wrong. It means you should treat them as a starting point for a conversation, not a prescription.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
MedSpa SLO · Instagram creator
67.7K views on this video
Everyone is talking about peptides right now… but do you actually know what they do? 👀 At Med Spa SLO Longevity Lounge, we’re breaking down the science and helping you understand which peptides may
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about pt-141 (bremelanotide)?
PT-141 (bremelanotide) is the only compound on this list with full FDA approval, specifically for hypoactive sexual desire disorder in premenopausal women, per the 2019 Simon et al. phase 3 data.
What does the video say about retatrutide showed up to 17.5% weight reduction in a 2023?
Retatrutide showed up to 17.5% weight reduction in a 2023 NEJM phase 2 trial, but it is not FDA-approved and should not be conflated with currently approved GLP-1 medications.
What does the video say about bpc-157 has zero completed randomized controlled trials in humans as?
BPC-157 has zero completed randomized controlled trials in humans as of 2024. All recovery claims for the 'Wolverine Stack' are based on animal model data only.
What does the video say about nad?
NAD is a coenzyme, not a peptide. Grouping it with peptide therapy is a category error that matters when evaluating mechanism claims.
What does the video say about compounded peptides?
Compounded peptides are not equivalent to FDA-approved drugs. Purity, sterility, and dosing consistency vary by pharmacy and are not subject to the same regulatory oversight.
What does the video say about dsip's supporting research?
DSIP's supporting research is largely from Soviet-era studies with methodological limitations. No modern peer-reviewed human trial supports calling it a sleep gamechanger.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by MedSpa SLO, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.